Pathogenica Bets on Next-Gen Sequencing for Fast, Multiplexed Pathogen Detection

The company, which is still exploring various next-gen sequencing platforms, plans to deploy its assay panels next year in a CLIA-certified lab setting and start testing them in clinical trials. It wants to launch an FDA-approved product by the end of 2012.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.